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ABSTRACT
 Objective: Myotonic dystrophy (DM) is a monogenic 
disorder. It is caused by expansion of a cytosine-thymine-
guanine triplet in the DMPK gene which encodes for 
myotonic dystrophy protein kinase (DMPK). 
 Methods: A 24-year-old man with DM and the 
DMPK mutation presented with elevated adrenocortico-
tropic hormone (ACTH) levels twice (152 and 185 pg/
mL; normal value is 10 to 52 pg/mL) with normal cortisol 
levels (134.6 and 113.0 ng/mL, or 371.3 and 311.7 nmol/L; 
normal values are 67 to 226 ng/mL or 184.8 to 623.5 
nmol/L). ACTH, corticotropin-releasing hormone (CRH) 
and insulin tolerance test (ITT) demonstrated normal corti-
sol response to ACTH and partial response to CRH and 
ITT tests, and ACTH hyperresponse to CRH and ITT. We 
suspected ACTH and/or ACTH receptor (ACTHR) muta-
tions and evaluated the genetic profile for pro-opiomela-
nocortin (POMC), melanocortin 2 receptor (MC2R) and 
follicle-stimulating hormone receptor (FSHR) genes. 
 Results: No mutations were found in either the MC2R 
or FSHR genes. The patient was heterozygous for the 
c.614A>G mutation corresponding to a p.53D>G substitu-
tion with a glycine instead of an aspartate in position 53 
in POMC gene. This mutation was outside the sequence 
for ACTH (which spans amino acids 138 to 176) but was 
included in the part originating the N-terminal peptide of 
pro-opiomelanocortin (also called pro-g-melanocyte stim-
ulating hormone) which spans amino acids 27 to 102 and is 
involved in the regulation of adrenal steroidogenesis. 
 Conclusion: The pathologic expansion of the cytosine-
thymine-guanine triplet repeat in the 3’ noncoding region 
of DMPK could explain the hyperresponse of ACTH typi-
cal of DM. The mutation of pro-g-melanocyte-stimulating 
hormone could be associated with the abnormal response 
of cortisol, compatible with a partial adrenal insufficiency. 
Other studies are necessary to demonstrate this hypothesis. 
(AACE Clinical Case Rep. 2019;5:e132-e137)
Abbreviations: 
ACTH = adrenocorticotropic hormone; CRH = corti-
cotropin-releasing hormone; DM = myotonic dystro-
phy; DMPK = myotonic dystrophy protein kinase; 
FSHR = follicle-stimulating hormone receptor; ITT = 
insulin tolerance test; MC2R = melanocortin 2 recep-
tor; MSH = melanocyte-stimulating hormone; POMC 
= pro-opiomelanocortin
INTRODUCTION
 Myotonic dystrophy (DM), or Steinert myotonic 
dystrophy, is one of the most common lethal monogenic 
disorders. It is caused by expansion of a cytosine-thymine-
guanine (CTG) triplet repeat in the 3’ noncoding region of 
the myotonic dystrophy protein kinase gene (DMPK). In 
the general population, the number of CTG repeats in this 
gene is between 5 to 37 while individuals with DM type 1 
have at least 50 and in some cases >3,000 CTG repeats. A 
second form of the disease known as DM type 2 has been 
recently recognized. This second form results in a CCTG 
repeat in the first intron of zinc finger 9 (1). 
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 The function of DMPK, the effects of CTG expansion 
on DMPK levels or structure, and the mechanisms lead-
ing to abnormalities in DM remain unclear. The multiple 
protein isoforms arising from the DMPK gene derive from 
alternative splicing (2). Moreover, the number of CTG 
repeats varies from tissue to tissue due to somatic mosa-
icism, thus explaining the wide phenotypic variation seen 
in DM (3).
 The spectrum of DM type 1 symptoms extends from 
lethal effects in infancy to mild, late-onset symptoms. 
The most frequent symptom is myotonia, usually more 
pronounced after rest, which improves after muscle activ-
ity (the so-called “warm-up phenomenon”). Myotonia 
selectively involves specific muscle groups of the forearm, 
hand, tongue, and jaw. Most frequent systemic symptoms 
are cardiac dysrhythmia (heart block particularly) (4), 
ocular symptoms (the most frequent is cataract), and neuro-
logical symptoms (daytime hypersomnolence and behav-
ioral and cognitive changes like anxiety, avoidant behavior, 
and apathy) (5). Other systemic features are gastrointes-
tinal symptoms (cholelithiasis and intestinal dysmotil-
ity) (6), higher risk of cancer (7,8), insulin resistance and 
dyslipidemia, and abnormal liver function (9). Primary 
hypogonadism is the most common endocrine alteration 
present in DM type 1, characterized by testicular atrophy, 
reduced fertility, erectile dysfunction, and low testosterone 
levels (10). 
 Some studies have reported that some DM type 1 
patients have altered hypothalamic-pituitary-adrenal axes, 
even in the absence of adrenal insufficiency symptoms, like 
increased adrenocorticotropic hormone (ACTH) response 
to corticotropin-releasing hormone (CRH) or insulin toler-
ance test (ITT) (11,12), or hyperresponse of ACTH after 
fenfluramine or naloxone test (13,14).
 Here, we report the case of a young man affected 
by DM type 1 with elevated ACTH levels in the absence 
of adrenal insufficiency symptoms with a variant in his 
pro-opiomelanocortin (POMC) gene coding for pro-g-
melanocyte-stimulating hormone (MSH).
CASE REPORT
Search for Genetic Alterations
 A blood sample was obtained after informed consent 
in accordance with local ethical committee guidelines. 
Genomic DNA was extracted from peripheral blood 
leukocytes using QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany). DNA concentration was assessed with 
NanoDrop One (Thermo Fisher Scientific, Waltham, MA). 
The entire coding regions of POMC, melanocortin 2 recep-
tor (MC2R, also known as ACTH receptor (ACTHR)), 
and follicle-stimulating hormone receptor (FSHR) genes 
were analyzed using end-point polymerase chain reac-
tion followed by denaturing high-performance liquid 
chromatography and direct sequencing. Primer sequences 
and polymerase chain reaction conditions are available 
upon request.
Biochemical Tests
 Serum thyroid-stimulating hormone, free triiodothy-
ronine, and free thyroxine were measured by chemilumi-
nescent immunometric assay (Immulite 2000; Siemens 
Medical Solutions Diagnostics, Los Angeles, CA). Cortisol 
levels were measured by immunoassay method using the 
Access Cortisol kit (Beckman Coulter, Inc., Brea, CA) 
with Beckman Coulter UniCel DxI 800 automatic analyz-
er. ACTH levels were measured by the immunometric 
chemiluminescence method with the Immulite 2000 XPI 
(Siemens AG, Munich, Germany) automatic analyzer using 
the ACTH kit (ACT Immulite 2000 systems; Siemens). 
Follicle-stimulating hormone, luteinizing hormone, and 
testosterone were evaluated using chemiluminescence 
performed with a commercial kit (Beckman Coulter). 
Dynamic Tests
Insulin Tolerance
 Intravenous insulin was administered (0.1 units/kg) 
with the intention of inducing hypoglycemia. Symptomatic 
hypoglycemia, with blood glucose values below 40 mg/
dL, is required to evoke a reliable central stress response 
with activation of the hypothalamic-pituitary-adrenal axis. 
Measurements were obtained at 0, 30, 45, 60, 90 and 120 
minutes with serum cortisol levels >200 ng/mL (>550 
nmol/L) indicating a normal response.
Adrenocorticotropic Hormone 
 This test evaluates the ability of the adrenal cortex to 
produce cortisol after stimulation by synthetic ACTH. The 
test was performed in the morning and 250 µg of Synacthen 
(which contains tetracosactide, a synthetic ACTH) was 
administered intravenously. Measurements were obtained 
at 0, 30, and 60 minutes with serum cortisol levels >200 
ng/mL (>550 nmol/L) indicating a normal response.
Corticotropin-Releasing Hormone
 Human CRH at a dose of 1.0 µg/kg body weight 
was injected intravenously as a bolus over 30 seconds. 
Measurements were obtained at 0, 30, 45, 60, 90, and 120 
minutes. Baseline ACTH increases 2 to 4-fold within 30 
to 60 minutes of CRH administration. Plasma cortisol 
typically peaks at >200 ng/mL (>550 nmol/L) within the 
same period.
Results
 A 24-year-old man received the diagnosis of DM type 
1 in 2014, after the appearance of myotonic myopathy. 
DMPK mutation was identified with a CTG amplification 
between 170 and 500 repetitions. Cardiac function was 
normal except for sinus bradycardia. 
 The patient came to our attention because the evidence 
of elevated follicle-stimulating hormone levels (29.8 mU/
mL; normal value is 0.7 to 11.0 mU/mL) with normal 
testosterone levels (6.35 ng/mL; normal value is 2.7 to 10.9 
ng/mL). His thyroid function, glycemia, insulin, hemoglo-
bin A1c, lipid levels, and liver function were all normal 
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(Table 1). Based on the literature, we also measured ACTH 
and cortisol levels at 8:00 am. ACTH levels, in 2 different 
samples, were 152 and 185 pg/mL (normal value is 10 to 
52 pg/mL) with normal cortisol levels of 134.6 and 113 
ng/mL, equal to 371.3 and 311.7 nmol/L (normal value is 
67 to 226 ng/mL, or 184.8 to 623.5 nmol/L). His aldoste-
rone and plasma renin activity levels were also normal. As 
described above, measurements of ACTH and CRH and an 
ITT were performed. The patient demonstrated a normal 
cortisol response to ACTH, partial responses to CRH and 
ITT, and ACTH hyperresponse to CRH and ITT (Table 2).
 Due to the elevated basal and stimulated ACTH levels 
associated with normal cortisol response, we suspected 
ACTH and/or ACTHR mutations and evaluated the genetic 
profiles of POMC, MC2R, and FSHR genes. No muta-
tions were found in either the MC2R or FSHR genes. 
However, the patient was heterozygous for the c.614A>G 
(rs28932470) mutation corresponding to a p.53D>G 
substitution with a glycine instead of an aspartate in posi-
tion 53 in POMC gene (Fig. 1 A). The reported minor allele 
frequency is 0.2 to 0.3% in the general population in the 
Ensembl and Genecard databases (Fig. 1 B). 
 Given that POMC is the precursor of several peptides 
including ACTH, we checked whether the p.53D>G modi-
fication could affect the ACTH protein sequence. As shown 
in Figure 1 C, this mutation was outside the sequence for 
ACTH (amino acids 138 to 176) but was included in the 
part originating the N-terminal peptide of pro-opiomela-
nocortin, also called pro-g-MSH (amino acids 27 to 102). 
Modeling of the D53G mutation was performed using the 
Swiss model server (http://swissmodel.expasy.org/) and 
the molecular visualization system Pymol (https://pymol.
org/2/) from the crystal structure of the normal protein 
(Fig. 2). The predicted phenotype for the variant was 
benign (PolyPhen software) and no splice sites were found 
to be associated (Human Splicing Finder version 3.1). 
 The parents were also analyzed for the c.614A>G 
mutation. The patient’s mother was found to be wild 
type, whereas the father carried the same alteration. The 
parents had normal basal levels of cortisol and ACTH; 
the father’s cortisol was 130.4 ng/mL (359.7 nmol/L) and 
ACTH was 33.2 pg/mL, the mother’s cortisol 140 ng/mL 
(386.2 nmol/L) and ACTH was 24 pg/mL. His father was 
also submitted to a CRH-stimulation test which showed 
partial response of cortisol without ACTH hyperresponse 
(Table 2).
DISCUSSION
 Diabetes mellitus and primary hypogonadism are 
endocrine manifestations typically seen in patients with 
DM type 1. In a few patients, abnormalities of the hypo-
thalamic-pituitary axis have also been reported (11-14). 
Earlier studies in DM type 1 patients showed an increased 
ACTH response to exogenous CRH and endogenous CRH 
Table 1 
Hormonal Results
Patient’s value Reference range
Aldosterone 86 pg/mL 70-295 pg/mL
Follicle-stimulating 
hormone 29.9 mU/mL 0.7-11 mU/mL
Free thyroxine 11.4 pg/mL 5.80-16.40 pg/mL
Free triiodothyronine 3.8 pg/mL 2.5-3.9 pg/mL
Insulin 5.3 IU/mL 2.6-34.9 IU/mL
Luteinizing hormone 7.5 mU/mL 0.8-8.0 mU/mL
Parathyroid hormone 23 pg/mL 10-60 pg/mL
Renin 3.2 ng/mL/hour 0.4-3.2 ng/mL/hour
Testosterone 6.63 ng/mL 2.7-10.9 ng/mL
Thyroid-stimulating 
hormone 1.43 µU/mL 0.4-4.0 µU/mL
Table 2
Test Results
Time 
(minutes)
ACTH test
(patient)
Corticotropin-releasing 
hormone test
Insulin tolerance test
(patient)
Cortisol 
(ng/mL)
Cortisol (ng/mL) ACTH (pg/mL) Cortisol 
(ng/mL)
ACTH 
(pg/mL)
Glycemia 
(mg/dL)Patient Father Patient Father
0 130.3 105.6 75.4 174.0 23.3 147.3 87.3 81
15 - 119.3 98.0 492.0 38.9 - - -
30 158.2 126.6 137.7 383.0 53.4 117.5 62.1 8
45 - - - - - 163.6 617.0 33
60 197.2 140.1 134.8 321.0 43.2 164.5 566.0 32
90 - - - - - 160.7 447.0 34
120 - 144.9 76.2 177.0 22.0 188.6 451.0 42
Abbreviation: ACTH = adrenocorticotropic hormone.
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induced by naloxone, fenfluramine, or insulin-induced 
hypoglycemia, concluding that the ACTH hypersecretion 
is due to a defect in the interaction between CRH and pitu-
itary corticotropin receptor or subsequent transduction.
 Our patient had elevated ACTH levels in the absence of 
adrenal insufficiency symptoms and a mutation (p.D53G) 
in pro-g-MSH (amino acids 27 to 102). It is known that 
g-MSH has synergistic properties on the action of ACTH 
both in vitro and in vivo (15,16). During the stress response, 
ACTH and g-MSH appear to coordinate the steroidogenic 
response of the adrenal gland. The g-MSH peptide potenti-
ates the response of ACTH by increasing the activity of 
the enzyme lipase, breaking down cholesterol esters to free 
cholesterol (17) and acting on adrenal mitogenesis and 
growth (18,19). Effects of g-MSH have also been reported 
on the cardiovascular system, a pressure effect concomi-
tant with an increase of heart rhythm and natriuresis. 
 Given the effects of g-MSH, a morphological defect in 
this peptide might have a role in abnormalities of the pitu-
itary-adrenal axis and cardiovascular system. Although the 
predicted phenotype for the p.D53G variant was benign, 
we can hypothesized from the 3-dimensional model of the 
protein that the substitution of aspartate with glycine may 
destabilize the protein. Aspartate is an α-amino acid with 
an acidic side chain (CH2COOH) which can react with 
other amino acids or enzymes. On the other hand, glycine 
is the is the simplest amino acid with only a hydrogen atom 
as its side chain. Due to their structural differences, we can 
hypothesize that the 53G variant differently interacts with 
other amino acids in the tridimensional structure and with 
other proteins, enzymes, or receptors compared to the wild 
type. Thus, the protein carrying the 53G variant may have a 
partial or diminished effect on its receptors, contributing to 
the clinical phenotype of DM characterized by endocrine 
dysfunctions and cardiac anomalies (including conduction 
block, tachyarrhythmia, sudden cardiac mortality, myocar-
dial disease, or ischemic heart disease). 
 However, the ACTH hyperresponse is probably linked 
also to the pathologic expansion of the CTG triplet in the 
3’ noncoding region of DMPK. In normal individuals, 
CRH initiates ACTH release by binding to specific recep-
tors on pituitary corticotropes, where cAMP-activated 
protein kinase-A is the essential link for the subsequent 
response cascade. Thus, it is possible to speculate that 
the DM mutation impacts the kinase pathway, leading to 
defective CRH-mediated signal transduction. Hockings et 
al (11) speculated on the abnormality of dihydropyridine-
insensitive calcium transport in the corticotropes through 
experiments using nifedipine and naloxone, suggesting an 
association between DMPK and the regulation of voltage-
dependent calcium channels.
 Our patient and his father have different ACTH secre-
tion responses (hypersecretion and normal secretion, 
respectively) but they have the same partial cortisol response 
to CRH. The absence of hyperresponse in the father, who 
shared the same mutation in pro-g-MSH, remains difficult 
Fig. 1. A, electropherogram showing the site of mutation (arrow). As indicated in the picture, the patient is heterozygous for c.614A>G. B, minor allele 
and genotype frequencies reported for the general population (Ensembl database). C, Sequence of pro-opiomelanocortin protein. In bold italic is shown 
the N-terminal peptide of pro-opiomelanocortin sequence with the arrow indicating the point of mutation. The sequence for adrenocorticotropic hormone 
is in bold.
A
B
C
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to explain. One hypothesis is that the p.53D>G substitu-
tion only partly affects the response of an adrenal gland to 
CRH. Another hypothesis could be because of the effect on 
adrenal growth, which could cause a primary insufficiency 
(19). The combination of p.53D>G in pro-g-MSH, together 
with a pathologic expansion of the CTG triplet in DMPK 
(which was absent in the father), could be responsible for 
the abnormal response of the hypothalamic-pituitary-adre-
nal axis observed in our patient, characterized by ACTH 
hyperresponse and cortisol partial response to CRH.
 One study on the pituitary-adrenal axis in DM patients 
showed differing results; some patients had normal ACTH 
and cortisol responses while others had hyperrespon-
sive ACTH but normal cortisol while still others showed 
inappropriately low cortisol responses independently of 
normal or supranormal ACTH responses (20). It would 
be interesting to determine the genetic profile in these 
subgroups of DM patients to better understand the different 
hormonal patterns. 
 It has been demonstrated that endocrine abnormali-
ties increase over time in patients with DM (21). Thus, we 
have suggested our patient undergo annual monitoring of 
hormonal status. In particular, because of the partial corti-
sol response to the CRH and ITT tests, we recommended 
to immediately report any high-stress incidents (such as 
illness, infection, fever, accidents, operations, or dental or 
medical procedures) and to keep hydrocortisone on hand 
for emergencies. 
CONCLUSION
 The pathologic expansion of the CTG triplet repeat in 
the 3’ noncoding region of DMPK could explain the hyper-
response of ACTH typical of DM patients. The resulting 
mutation in pro-g-MSH could be associated with the abnor-
mal response of cortisol, compatible with partial adrenal 
insufficiency. Other studies are necessary to demonstrate 
this hypothesis in DM patients.
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